AllianceBernstein’s 4D Molecular Therapeutics FDMT Stock Holding History

AllianceBernstein’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$413K	Hold	55,100	–	–	﹤0.01%	2733
2025 Q4	$413K	Sell	55,100 -10,190	-16%	-$103K	﹤0.01%	2752
2025 Q3	$567K	Hold	65,290	–	–	﹤0.01%	2616
2025 Q2	$242K	Buy	65,290 +9,420	+17%	+$33.1K	﹤0.01%	3004
2025 Q1	$180K	Hold	55,870	–	–	﹤0.01%	2949
2024 Q4	$311K	Hold	55,870	–	–	﹤0.01%	2849
2024 Q3	$604K	Hold	55,870	–	–	﹤0.01%	2570
2024 Q2	$1.17M	Buy	55,870 +19,320	+53%	+$485K	﹤0.01%	2217
2024 Q1	$1.16M	Buy	36,550 +6,380	+21%	+$163K	﹤0.01%	2178
2023 Q4	$611K	Sell	30,170 -53,100	-64%	-$699K	﹤0.01%	2511
2023 Q3	$1.06M	Sell	83,270 -5,370	-6%	-$89.8K	﹤0.01%	2206
2023 Q2	$1.6M	Buy	88,640 +71,540	+418%	+$1.32M	﹤0.01%	2032
2023 Q1	$294K	Hold	17,100	–	–	﹤0.01%	2777
2022 Q4	$380K	Buy	+17,100	New	+$264K	﹤0.01%	2775

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AllianceBernstein's FDMT Position: Q1 2026 in Review

AllianceBernstein held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 55,100 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #2733.

AllianceBernstein first reported a position in FDMT in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.6M in Q2 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

AllianceBernstein held 55,100 shares of 4D Molecular Therapeutics worth $413K as of Q1 2026.
AllianceBernstein left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
4D Molecular Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2733 holding.
AllianceBernstein first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 14 quarters since.
AllianceBernstein's 4D Molecular Therapeutics position peaked at $1.6M in Q2 2023.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.